肿瘤免疫检查点抑制剂治疗不良反应及其治疗——皮肤  

Cutaneous adverse events caused byimmune checkpoint inhibitors：classification and management

作　　者：聂芳芳[1] 付杰[1] Nie Fangfang , Fu Jie(Department of Radiation Oncology, Shanghai Jiaotong University Affliated Sixth People＇ s Hospital, Shanghai 200233, Chin)

机构地区：[1]上海交通大学附属第六人民医院肿瘤放疗科,200233

出　　处：《中华放射肿瘤学杂志》2018年第3期331-334,共4页Chinese Journal of Radiation Oncology

基　　金：上海申康医院发展中心促进市级医院临床技能与临床创新能力三年行动计划（16CR3112B）

摘　　要：免疫检查点抑制剂（ICPIs）已成功应用于多种恶性肿瘤的治疗，但在应用的过程中也会发生免疫相关不良反应（irAEs）。皮肤不良反应为常见的irAEs，病变较轻者主要表现为斑丘疹、苔藓样皮炎、大疱性类天疱疮、白癜风、银屑病和硬皮病；病情较重甚至危及生命的皮肤不良反应包括史提芬强生症候群和中毒性表皮坏死松解症；其他包括药疹伴嗜酸性粒细胞增多和系统症状、Sweet’s综合征、秃头症、Grover’s病和副肿瘤综合征等。本文将对ICPIs治疗相关皮肤不良反应诊治进行综述。Immune checkpoint inhibitors （ICPIs） have been successfully used in the treatment of multiple malignancies. However, immune-related adverse events （irAEs） may occur during treatment. Cutaneous adverse event （ CAE ） is acommon type of irAE. Mild CAEs include maculopapule, lichenoid reaction, bullous pemphigoid ,vitiligo ,psoriasis, and scleroderma. Severe and even life-threatening CAEs include Steven-Johnson syndromeand toxic epidermal necrolysis. Other CAEs include drug reactionwith eosinophiliaand systemic symptoms,Sweet＇s syndrome,alopecia, Grover＇s disease, and paraneoplastic syndrome. This paper reviews the treatment of cutaneous adverse events associated with ICPIs.

关 键 词：免疫检查点抑制剂 免疫相关不良反应 皮肤不良反应 

分 类 号：R730.51[医药卫生—肿瘤]